Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 5/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | EYA2 | O00167 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108591 | 0.89 | KMT2A (0.44) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL20371103 | 0.89 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL3792078 | 0.88 | KMT2A (0.54) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL28416919 | 0.87 | KMT2A (0.40) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL31040664 | 0.87 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL28414420 | 0.87 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL21838102 | 0.87 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL30861809 | 0.87 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2 | |
| SCHEMBL307644 | 0.86 | KMT2A (0.41) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL29883728 | 0.86 | KMT2A (0.41) | KMT2AFABP5FABP7TLR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592940-B | Biological enzyme synthesis method of N- (9-fluorenylmethoxycarbonyl) -decylaminoacetaldehyde | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-112592940-B | Biological enzyme synthesis method of N- (9-fluorenylmethoxycarbonyl) -decylaminoacetaldehyde | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111233713-A | Synthesis method of telavancin intermediate | 福建康鸿生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20190153036-A1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2019-05-23 | — | — | US | disclosed |
| US-8859506-B2 | Glycopeptide phosphonate derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8541375-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120283195-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-8101575-B2 | Glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8093354-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030008812-A1 | Glycopeptide derivatives | THERAVANCE, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6455669-B1 | GLYCOPROTEIN FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THERAVANCE, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001057071-A2 | GLYCOPEPTIDE DERIVATIVES HAVING ANTIBIOTIC ACTIVITY | ADVANCED MEDICINE, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024604-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885FABP5 2120/4885FABP7 3340/4885 |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | GYPA, VIP, OGT | KMT2A 4121/4885FABP5 3659/4885FABP7 4012/4885 |
| US-20030008812-A1 | Glycopeptide derivatives | MGAT3, GYPA, GIPR | KMT2A 4608/4885FABP5 2718/4885FABP7 3062/4885 |
| US-20120283195-A1 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | PAG1, PGLS, PTMS | KMT2A 4796/4885FABP5 2120/4885FABP7 3340/4885 |
| US-20190153036-A1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PEPD, VIP, NRDC | KMT2A 4210/4885FABP5 3581/4885FABP7 4170/4885 |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | GLS, PIGS, PAG1 | KMT2A 4773/4885FABP5 1107/4885FABP7 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.